Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

Código QR

Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

Shelly Wen,1,2 Lucy Manuel,1,2 Moira Doolan,1,2 Justin Westhuyzen,1 Thomas P Shakespeare,1,2 Noel J Aherne1,2 1Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia; 2University of New South Wales, Sydney, New South Wales, AustraliaCorresponden...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wen S, Manuel L, Doolan M, Westhuyzen J, Shakespeare TP, Aherne NJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	dose fractionation mastectomy radiotherapy survival analysis triple negative breast neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3fe806037f754fe6842947b0f7c06c77
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
por: Saliha Karagöz Eren, et al.
Publicado: (2021)

Tratamiento conservador del carcinoma ductal in situ de la mama
por: Hepp,Rodrigo, et al.
Publicado: (1999)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Resultados del tratamiento del cáncer de mama, Programa Nacional de Cáncer del Adulto
por: Castillo,César del SM., et al.
Publicado: (2017)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 2A (OBFC2A) in Triple-Negative Breast Cancer
por: Qianxue Wu, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
por: A. I. Chertkova, et al.
Publicado: (2018)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Costo beneficio del estudio de diseminación en estadios I y II del cáncer de mama
por: Camacho N,Jamile, et al.
Publicado: (2003)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Cancer de mama oculto: dos casos clínicos analizados según el concepto actual
por: Lee Ch,Kuen, et al.
Publicado: (2006)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
por: Cook MT, et al.
Publicado: (2016)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie SM, et al.
Publicado: (2018)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)

Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer
por: Zheng H, et al.
Publicado: (2016)

A Novel Prognostic Model Based on the Serum Iron Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Xin Hua, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jesse Lopes da Silva, et al.
Publicado: (2021)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells
por: Chia-Che Chang, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Fangfang Duan, et al.
Publicado: (2021)